---
title: "Morgan Stanley: WUXI XDC stock price will absolutely rise in the next 30 days"
description: "Morgan Stanley predicts that WUXI XDC's stock price will rise in the next 30 days, as the recent price drop has made short-term valuations more attractive. WuXi AppTec announced a significant external"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277401620.md"
published_at: "2026-03-02T03:58:19.000Z"
---

# Morgan Stanley: WUXI XDC stock price will absolutely rise in the next 30 days

> Morgan Stanley predicts that WUXI XDC's stock price will rise in the next 30 days, as the recent price drop has made short-term valuations more attractive. WuXi AppTec announced a significant external licensing agreement involving its payload connector technology platform, which is expected to enhance sales and profitability. Morgan Stanley has set a target price of 86 yuan for the stock, with a rating of "Overweight."

Morgan Stanley issued a technical opinion report, believing that WuXi XDC (02268.HK) stock price will rise in absolute terms over the next 30 days, mainly due to the recent decline in the stock's trading price, making short-term valuations more attractive. WuXi AppTec announced a substantial external licensing agreement involving its payload connector technology platform. Such agreements include upfront payments, milestone payments, and potential sales royalties, all of which will help enhance sales and profitability.

The bank set a target price of 86 yuan for WuXi XDC, with a rating of "Overweight."

### Related Stocks

- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [588860.CN - ICBCCS SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588860.CN.md)
- [603259.CN - WuXi AppTec](https://longbridge.com/en/quote/603259.CN.md)
- [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md)
- [516500.CN - ChinaAMC CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/516500.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [02269.HK - WUXI BIO](https://longbridge.com/en/quote/02269.HK.md)
- [588130.CN - ChinaAMC SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588130.CN.md)
- [02268.HK - WUXI XDC](https://longbridge.com/en/quote/02268.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 漢霖生物在 2/3 期乳腺癌藥物研究中為首位患者用藥；股價下跌 3% | 恆瑞醫藥在二期/三期乳腺癌藥物研究中為首位患者給藥；股價下跌 3% | [Link](https://longbridge.com/en/news/277421361.md) |
| 野村證券將藥明合聯開曼的目標價從 82.72 港元上調至 87.73 港元，並維持買入評級 | 野村將藥明合聯（WuXi XDC Cayman）的目標價從 82.72 港元上調至 87.73 港元，維持 “買入” 評級 | [Link](https://longbridge.com/en/news/275736820.md) |
| 根據港交所顯示，貝萊德在藥明康德 H 股的多頭頭寸從 2 月 16 日的 5.22% 減少至 4.51% | 根據香港交易所的數據，貝萊德在藥明康德的 H 股的多頭頭寸在 2 月 16 日降至 4.51%，之前為 5.22% | [Link](https://longbridge.com/en/news/276436772.md) |
| 藥明合聯發佈了現金收購 TOT BIOPHARM 的要約文件 | WuXi XDC Cayman Inc. 已經發出了自願現金收購 TOT BIOPHARM International Co. Ltd. (HK:1875) 的要約文件，排除已由要約方持有的股份。該要約將於 2026 年 2 月 12 日開 | [Link](https://longbridge.com/en/news/275675866.md) |
| Top 5 港股千億以上公司漲跌幅（2月26日） | 東方電氣 (01072) 涨 15.52%，成交额 14.1 亿港元，年内累计涨 62%。 豪威集團 (00501) 涨 6.91%，成交额 1.7 亿港元，年内累计涨 4.8%。 百濟神州 (06160) 跌 9.16%，成交额 12.1 | [Link](https://longbridge.com/en/news/277006258.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.